IMM-2019611

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameIMM-2019611
Drug Alias NameMAPK signaling pathway inhibitor (Immuneering)trifecta MEK (Immuneering)IMM-2019611
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase inhibitors
TargetsMitogen-activated protein kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmuneering Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmuneering Corp
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A